1Department of Pharmacology, Uttaranchal Institute of Pharmaceutical Sciences (UIPS), Uttaranchal University, Dehradun - 248007, Uttarakhand, India
2Faculty of Pharmacy, DIT University, Dehradun - 248009, Uttarakhand, India
3Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India-140401
One of the main causes of death in the globe is cancer. It is uncontrolled proliferation of abnormal cell and can be malignant or non-malignant. Treatment of cancer via chemotherapeutic agents and radiation has been used since long. But due to their harmful effects and due to MDR (Multi Drug Resistance), use of herbal medicine has been the new approach. p53 (protein 53) gene also known as suppressor gene, is responsible for taking part in metabolic processes like apoptosis, DNA (Deoxyribonucleic Acid) repair and cell cycle arrest. The 393 amino acids that make up the p53 protein are divided into six domains. First is the N-terminal region, which is separated into two parts and contains the Transcription Activation Domain (TAD) (TD1 and TD2). The Proline-Rich Region (PRR), which is consistent in most p53s, comes in second. The DNA-binding portion of the central core domain (p53C), where more than 90% of human mutations occur, is ranked third. A nuclear localization signal domain comes in fourth. A tetramerization (TET) domain comes in fifth. The C-terminal domain (CT), a general DNA-binding domain, comes in at number six. So p53 is the target of many anti cancer drugs. Mutant versions of the tumor-suppressor p53 (mutp53) commonly develop tumor-promoting features in addition to losing their tumor-suppressive ones.The development of p53-targeted medications is particularly difficult since the agent must identify areas of improvement in mutp53 cancer cells while having no impact on healthy cells with wtp53 (wild type p53).
P53, Apoptosis, Tumor, Cancer, Eupatorium adenophorum, Murine double minute 2, Bax